Johnson & Johnson is a US multinational pharmaceutical and medical devices company incorporated in New Jersey in 1887 and headquartered in New Brunswick, New Jersey.
Is this your business? Add your evidence →
J&J's Scope 1 and 2 emissions fell 38% from 2021, mostly through renewable electricity instruments including unbundled certificates; Scope 1 itself fell only about 3% from 2023 to 2025. It reports Scope 3 by category but states no total, and says most of the recent fall in its largest categories comes from a 2025 methodology change. Only 37% of key suppliers have science-based targets, and its trade-association dues go to groups opposing climate policy.
Johnson & Johnson scores 38/100 (Below expectations) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified October 2026.
That places Johnson & Johnson joint 410th of 847 companies scored, and 15th of 19 in Healthcare / Pharmaceuticals.
Where Johnson & Johnson sits among healthcare / pharmaceuticals peers.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Johnson & Johnson sits 15th of 19.
Its three lowest-scoring questions, and what the evidence didn't show.
No quantified nature footprint, verified deforestation-free policy, or TNFD-aligned disclosure found.
Electricity is 46% of total energy; natural gas use rose to 912,320 MWh, and vehicle fleet remains fossil-fuelled.
As You Sow rates plastic commitments D-; no published circularity target.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Carbon Footprint — Supply Chain (8/10, 7/10). Weakest on Nature & Biodiversity Impact and Energy Source (4/10, 5/10).
The 3 companies in the sector scoring nearest above Johnson & Johnson.
Convatec has achieved credible operational carbon reductions (62% Scope 1+2 by 2024) backed by SBTi validation, but Scope 3—representing 94% of footprint—targets intensity, not absolute cuts.
See the breakdown →Merck reports emissions via GHG Protocol with third-party assurance, but buries specific figures in CDP filings.
See the breakdown →Pfizer discloses robust climate data with GHG Protocol alignment and SBTi validation, but progress is dire: only 15% of its 46% emissions reduction target achieved by 2024, renewable energy stuck at 14% despite RE100 membership, and hazardous waste flat since 2022.
See the breakdown →Johnson & Johnson's score has moved from 41 to 38 across 2 recorded reviews, down 3 points.
Fortune 50 re-score (owner-approved batch 2, 2026-10-17)
Initial score at platform launch
The formula and all 9 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale9 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
“Market-based 42,811”
“Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.”
“We have used the LEAP (Locate, Evaluate, Assess, Prepare) approach, developed by the Taskforce on Nature-related Financial Disclosures (TNFD)”
“In addition to our climate goals, we also have a longer-term ambition to reach net zero emissions by 2045.”
“39.1% in Forest 500 Rankings”
If you believe a source has been misread or a newer version exists, submit a challenge.
Johnson & Johnson is a US multinational pharmaceutical and medical devices company incorporated in New Jersey in 1887 and headquartered in New Brunswick, New Jersey. With FY2025 revenue of $94.2 billion and 138,200 employees, it ranks among the world's largest healthcare manufacturers, spanning prescription drugs, vaccines, consumer health, and medical technology.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.